The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 08, 2017

Filed:

Nov. 06, 2013
Applicant:

Hanmi Pharm. Co., Ltd., Hwaseong-si, Gyeonggi-do, KR;

Inventors:

Hyun Uk Kim, Hwaseong-si, KR;

Hyung Kyu Lim, Hwaseong-si, KR;

Myung Hyun Jang, Seoul, KR;

Sang Yun Kim, Gimpo-si, KR;

Sung Min Bae, Seongnam-si, KR;

Se Chang Kwon, Seoul, KR;

Assignee:

Hanmi Pharm. Co., Ltd., Hwaseong-Si, Gyeonggi-Do, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/08 (2006.01); A61K 38/26 (2006.01); A61K 47/48 (2006.01); C07K 14/605 (2006.01); A61K 47/26 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01);
U.S. Cl.
CPC ...
A61K 47/26 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 38/26 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/48369 (2013.01); A61K 47/48415 (2013.01); C07K 14/605 (2013.01); C07K 2319/30 (2013.01);
Abstract

Disclosed are an albumin-free liquid formulation including a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, and a method for preparing the liquid formulation. The liquid formulation contains a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. The oxyntomodulin conjugate contains oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.


Find Patent Forward Citations

Loading…